

MEDICATION NAME:	AVATROMBOPAG BRAND: DOPLETET
HOW IS IT GIVEN:	Oral tablet.
HOW DOES IT WORK:	Binds to the thrombopoietin receptor on megakaryocytes which stimulates platelet production.
COMMON DOSING REGIMENS:	<u>Starting dose</u> is 20 mg once a day. <u>Maximum dose</u> 40mg per day. Dosage should be lowered if the platelet count exceeds 400 x10 ⁹ /L. ASA or another drug may be indicated for some patients with a high platelet count to reduce the risk of thrombosis.
COMMON SIDE EFFECTS:	Unusual weight gain or loss.
RARE BUT SERIOUS SIDE EFFECTS:	The risk of thrombosis (blood clots) and bone marrow reticulin (fibrous scarring) has not been established.
TYPICAL TIME TO RESPONSE:	1-3 weeks.
LIKELIHOOD OF INITIAL RESPONSE:	Approximately 66% of patients attain a platelet count of 50 x 10 ⁹ /L or greater on day 8.
LIKELIHOOD OF LONG-TERM RESPONSE (3-5 YEARS):	Not enough is known at this time.
OTHER CONSIDERATIONS:	To be taken with food. The prevalence of sustained remission off treatment has not been established. Not recommended for use during pregnancy.

References

1. Al-Samkara, H and Kuter, D.J. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Therapeutic advances in hematology 2019;10:1-13.
2. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014; 123: 3887–3894.
3. Ghanima, W et al. “Thrombopoietin receptor agonists: ten years later.” Haematologica. 2019 Jun; 104(6): 1112-1123.
4. Jurczak, W et al. “Phase 3 randomized study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.” British Journal of Haematology. 2018 Nov; 183(3): 479-490.
5. Platelet disorder support association: <https://www.pdsa.org/platelet-growth-factors.html>
6. <https://www.chemoexperts.com/avatrombopag-doptelet-itp.html>